

Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012

Keita Wada · Kyoichi Takaori · L. William Traverso · Ralph H. Hruban ·
Toru Furukawa · Teresa A. Brentnall · Takashi Hatori · Keiji Sano ·
Tadahiro Takada · Yoshiyuki Majima · Tooru Shimosegawa

Published online: 19 April 2013

© Japanese Society of Hepato-Biliary-Pancreatic Surgery and Springer Japan 2013

Abstract Pancreatic cancer is still a highly lethal disease with a 5-year survival rate of approximately 5 %. Early detection offers one of the best hopes for improving survival. Previous cohort studies and case–control studies showed that 4–10 % of pancreatic cancers have a hereditary basis, and individuals with a family history have an increased risk of developing pancreatic and extra-pancreatic malignancies. Since individuals with a family history of pancreatic cancer and those with a known genetic syndrome that predisposes to pancreatic cancer will be the first to benefit from early detection tests as they become available, familial pancreatic cancer (FPC) registries have been established in the US and Europe, but not yet in Japan. Such registries form the basis for epidemiological studies, clinical trials, and basic research on familial pancreatic cancer. There is a need for FPC registries in Japan

as cancer risk varies among different populations and discoveries made in Western populations may not translate to the Japanese population. These registries in Japan will align with ongoing international efforts and add to a better understanding of the natural history, risk factors, screening strategies, and responsible genes, for improving survival of this dismal disease.

Keywords Familial pancreatic cancer · Risk factors · Screening

Introduction

Pancreatic cancer (PC) is the 5th leading cause of cancer-related death (>28,000 per year) in Japan, and the

K. Wada (✉) · K. Sano · T. Takada
Department of Surgery, Teikyo University School of Medicine,
2-11-1 Kaga Itabashi-ku, Tokyo 173-8605, Japan
e-mail: wada@med.teikyo-u.ac.jp

K. Takaori
Division of Hepato-Biliary-Pancreatic Surgery and
Transplantation, Department of Surgery, Kyoto University
Graduate School of Medicine, Kyoto, Japan

L. W. Traverso
Department of General Surgery, St. Luke's Center for Pancreatic
Disease, Boise, ID, USA

R. H. Hruban
Department of Pathology, The Sol Goldman Pancreatic Cancer
Research Center, Johns Hopkins Medical Institutions, Baltimore,
MD, USA

T. Furukawa
Institute for Integrated Medical Sciences, Tokyo Women's
Medical University, Tokyo, Japan

T. A. Brentnall
GI Division, Department of Medicine, University of
Washington, Seattle, WA, USA

T. Hatori
Department of Surgery, Institute of Gastroenterology, Tokyo
Women's Medical University, Tokyo, Japan

Y. Majima
Pancreatic Cancer Action Network, Tokyo, Japan

T. Shimosegawa
Division of Gastroenterology, Tohoku University Graduate
School of Medicine, Sendai, Japan

incidence is increasing [1]. According to the 30-year experience of the Japan Pancreatic Cancer Registry, the overall survival rate has been improving decade by decade for both resected and non-resected cases, with an overall 5-year survival of 18.8 % for resected cases registered between 2001 and 2007 [2]. These improvements are believed to be due to better patient selection, refinements in surgical techniques, and better postoperative patient care, in addition to effective adjuvant therapies. However, given the low incidence of resectable PC (20–30 % in general), the overall 5-year survival can be estimated at around 5 % at best, which is still the worst among gastrointestinal (GI) and non-GI solid malignancies [3].

Early detection and prevention offer the best hopes for reducing the mortality from pancreatic cancer. The survival rate of invasive PC is stage-dependent, and the survival for early disease is favorable [2, 3]. It is reported that small tumors ≤ 10 mm in diameter (T1a) have a favorable prognosis of >80 % at 5 years [2]. Furthermore, many invasive pancreatic cancers arise from non-invasive precursor lesions, such as intraductal papillary mucinous neoplasms (IPMN), and these non-invasive lesions are completely curable. These observations suggest that screening for pancreatic cancer may save lives, but screening the general population is problematic given the low incidence of PC in the general population (8.5–12 per 100,000 per year) [4, 5]. Hence, the identification of high-

risk individuals (HRIs) is crucial for screening programs in PC.

Several environmental and genetic risk factors for developing PC have been identified and are summarized in Table 1 [6–19] and Table 2 [20–37]. Cigarette smoking is the strongest environmental risk factor for PC, with an increased odds ratio (OR) of 1.7–2.2 [6–9]. Diabetes mellitus and chronic pancreatitis also both increase risk, and both can also be a sign of the disease. Although most PC cases are sporadic in nature, up to 10 % of cases can be attributed to genetic predisposition [38, 39]. Familial pancreatic cancer (FPC) is a term once widely used to describe a general clustering of PC in a family, but FPC is now more specifically defined as a family in which at least two first-degree relatives (FDR) have been diagnosed with PC. In some FPC kindreds the disease appears to have an autosomal dominant inheritance with variable penetrance [40, 41]. Although less well-established, it has also been suggested in some, but not all, studies that some patients with FPC have a younger onset (by 5 years) [42–44], anticipation [45, 46], and worse prognosis [45, 47].

Registries of kindreds with FPC have proven invaluable for epidemiological studies, clinical trials, and basic research, but such registries have not been established in Japan. This is particularly problematic because the gene or genes responsible for the aggregation of pancreatic cancer in the Japanese population may be different from those responsible for FPC in the Western population.

Based on the above mentioned background, a kick-off meeting was held during the International Symposium on Pancreas Cancer 2012 which took place in October 4–6, 2012 in Kyoto, Japan. In this article, the history and current status of FPC is described while emphasizing the emerging necessity for a FPC registry in Japan.

Epidemiology of familial pancreatic cancer

Adenocarcinoma-prone families, including families predisposed to PC, were reported by Henry Lynch [48] as early as in 1967, and MacDermott and Kramer [49]

Table 1 Non-genetic factors associated with pancreatic cancer

Risk factors	Risk level	References
Smoking	OR 1.7–2.2	[6–9]
Obesity	RR 1.1–1.4	[10, 11]
Alcohol abuse	OR 1.2–1.6	[12, 13]
Diabetes	RR 1.8–1.9	[14–16]
New onset type II diabetes	OR 2.1	[14, 15]
Chronic pancreatitis	SIR 13–14	[17, 18]
IPMN	SIR 16	[19]

OR odds ratio, RR relative risk, SIR standardized incidence ratio

Table 2 Hereditary cancer syndromes associated with an increased risk of pancreatic cancer

Syndrome	Gene	Inheritance	Relative risk	Risk by age 70	References
Peutz–Jeghers syndrome (PJS)	<i>SKT11, LKB1</i>	AD	132	11–36 %	[20, 21]
Hereditary pancreatitis (HP)	<i>PRSS1, SPink1, CTRF</i>	AD	50–70	40–55 %	[22–24]
Familial atypical multiple mole melanoma (FAMMM)	<i>p16INK4a/MTS1</i>	AD	34–39	17 %	[25–28]
Hereditary breast ovarian cancer (HBOC)	<i>BRCA1, BRCA2</i>	AD	4.5	2–7 %	[29–33]
Hereditary nonpolyposis colon cancer (HNPCC)	<i>MSH2, MLH1, MSH6, etc.</i>	AD	4.7–8.6	<5 %	[34–37]
Familial Pancreatic Cancer (FPC)	<i>PALB2, ATM</i>	AD	Not known	Not known	[100, 101]

AD autosomal dominant

described a pedigree in which 4 of 6 siblings were diagnosed with PC in 1973. These early reports were followed by several more case series [50–53]. Since then population-based, case–control studies and cohort studies have been conducted, and a family history of PC is recognized as a risk factor for PC, with 4–10 % of patients with PC reporting a family history of the disease [38, 39]. In 1991 Ghadirian and colleagues [54] reported the result of a Canadian population-based case–control study showing that 7.8 % of patients with PC and only 0.6 % of controls had a family history of PC, a 13-fold difference between cases and controls. Larger case–control studies have also shown an increased risk level, with an OR of 2.1–3.8 among individuals with a family history of PC compared with those without such a history [55–57]. Similarly, prospective cohort studies showed a relative risk (RR) of 1.5–1.7 [58–61], indicating that having a single close relative with PC doubles one’s risk of developing PC.

The Pancreatic Cancer Genetic Epidemiology (PAC-GENE) consortium, which is a FPC consortium of multiple centers in North America, reported that mean age \pm SD at diagnosis among 369 FPC probands and 429 relatives was 65.4 ± 11.6 years, which was significantly younger than the mean age at diagnosis in the Surveillance, Epidemiology and End Result (SEER) population (70.0 ± 12.1 years; $P < 0.001$) [43]. Other studies from a European registry have suggested genetic anticipation, which refers to younger onset in successive generations in familial disease [45, 46]. Similarly, a registry-based prospective study from the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) and the German National Case Collection for Familial Pancreatic Cancer (FaPaCa) reported on 80 affected child–parent pairs, and found that the children died of their disease a median of 10 years earlier than did their parents. The median age of death from PC was 70, 64, and 49 years in Generations G1, G2, and G3 [45]. These observations are important for determining the most appropriate age at which to commence screening for PC in individuals at high-risk.

FPC is currently defined as kindred in whom at least a pair of first-degree relatives have been diagnosed with pancreatic cancer. In most instances the gene responsible for this clustering is not known, although a few cancer-predisposing syndromes are known and are summarized in Table 2. Klein and colleagues prospectively followed more than 5,000 individuals from 838 kindreds enrolled in the National Familial Pancreas Tumor Registry (NFPTR) at Johns Hopkins University [61]. A standardized incidence rate (SIR) was calculated by comparing the numbers of observed PC cases with those expected using SEER rates. The SIR for developing PC was significantly elevated in members of FPC kindreds [SIR = 9.0; 95 % confidence interval (CI), 4.5–16.1], but not in the sporadic PC kindreds

Table 3 Risk and incidence of pancreatic cancer in familial pancreatic cancer kindreds [42]

Number of FDRs with pancreatic cancer	SIR (95 % CI)	Incidence (per 100,000) in the general US population
3 or more FDRs	32 (10.4–74.7)	288
2 FDRs	6.4 (1.8–16.4)	58
1 FDR	4.5 (0.54–16.3)	41
General population	1	9

FDR first-degree relative, SIR standardized incidence rate, CI confidence interval

[SIR = 1.8; 95 % CI, 0.22–6.4] or in the unrelated kindreds [SIR = 2.4, 95 %CI, 0.06–13.5]. This risk in FPC kindreds was elevated in individuals with two affected FDRs with PC who had a 6.4-fold increased risk (95 % CI, 1.8–16.4), and individuals with 3 or more FDRs with PC who had a 32.0-fold increased risk (95 % CI, 10.4–74.7), as summarized in Table 3 [61]. By using these observations Wang and colleagues established risk prediction software, called PancPRO, that can be used to quantify an individual’s risk of developing PC based on the family history of PC [62]. This software is publicly available.

Individuals having a strong family history of PC also have an increased risk of developing extra-pancreatic cancer. Wang and colleagues reported elevated cancer mortality in the relatives of patients with PC, showing that cancer mortality was increased in the relatives of both sporadic and familial PC probands. Relatives of familial probands had a significantly increased risk of dying from breast cancer, ovarian cancer, and bile duct cancers [47]. The Pancreatic Cancer Cohort Consortium (PanScan) study, an international collaborative nested case–control study investigating the association between a family history of 5 types of cancer (pancreas, prostate, ovarian, breast, and colorectal) and risk of PC, found that a family history of PC and prostate cancer was associated with increased risk of PC [60].

Familial pancreatic cancer registries and consortiums

There are a number of established FPC registries in the US, Canada, Europe, and Australia, but not in Japan. The National Familial Pancreas Tumors Registry (NFPTR) at Johns Hopkins Hospital is the first and largest registry in the world (<http://pathology.jhu.edu/pc/nfpnr/index.php>), and was established by Dr. Ralph H. Hruban in 1994. The primary goals of the registry were three-fold: understanding the risk of PC, identifying genetic and non-genetic causes of PC, and facilitating the early detection of PC. As of February 2013, more than 4,569 families with at least one PC have been enrolled in the NFPTR, of which 1,447

meet criteria for FPC. A number of pivotal research studies have been conducted using this registry. It was followed by other high-volume centers in the US. In Europe, the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) at Liverpool University (Liverpool, UK) and the German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa) at Phillips University (Marburg, Germany) were established in 1999, followed by a National Registry for Familial Pancreatic Cancer in Italy, the Spanish National Hereditary Pancreatic Cancer Registry (PanFAM) in Spain, the Australian Familial Pancreatic Cancer Cohort (AFPACC) in Australia, etc.

In 2002 the Pancreatic Cancer Genetic Epidemiology (PACGENE) consortium was organized with funding from the National Cancer Institute and data collection is ongoing in high-volume centers in the US and Canada, including the Dana–Farber Cancer Institute (Boston, MA, USA), Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins University (Baltimore, MD, USA), Karmanos Cancer Institute–Wayne State University (Detroit, MI, USA), Mayo Clinic (Rochester, MN, USA), Creighton University (Omaha, NE, USA), and University of Toronto (ON, Canada) [43]. The objective of this consortium is to identify susceptibility genes for PC using linkage analysis in order to improve risk assessment, aid in the early detection of PC, and help point to new strategies for screening, prevention, and treatment. In Europe, the European PANGEN PC case–control study is also organized for an EU-wide multicenter case collection.

Currently, epidemiological studies, risk analysis, basic research, and clinical trials on early detection are being conducted based on the abovementioned FPC registries and consortia, which necessitates an FPC registry in Japan.

Screening in familial pancreatic cancer registries and consortia

The goal of the screening of PC is to detect curable high-grade precursor lesions such as pancreatic intraepithelial neoplasia (PanIN) [63–67], intraductal papillary mucinous neoplasms (IPMN), and mucinous cystic neoplasms (MCN) [68–73], as well as early small adenocarcinomas [2]. When found, these lesions can be surgically resected and lives saved. Despite recent improvements in imaging modalities allowing the detection of small cystic and solid lesions, it is still uncertain whether or not PanIN lesions can be detected. However, over the past two decades, screening of individuals at high risk based on FPC registries has provided increasing insights into the precursor lesions in patients with a family history of pancreatic cancer [74, 75].

One of the first reports on screening FPC kindreds came from the University of Washington in 1999 [76]. Brentnall and colleagues studied 14 individuals from three families with strong family histories of PC, using computed tomography (CT), endoscopic ultrasound (EUS), and endoscopic retrograde cholangiopancreatography (ERCP). Of note, multiple family members were affected in one of the three families (Family X). In this family, nine family members have died of PC without any evidence of hereditary pancreatitis, hereditary nonpolyposis colon cancer, or *p16* germline mutation. On EUS findings, ten out of 14 screened family members (71 %) had abnormal results including heterogeneous parenchyma with 1- to 2-mm scattered echogenic foci, hypoechoic nodules 2–4 mm in diameter, hyperechoic main-duct walls, discrete masses, and findings similar to those of chronic pancreatitis. Findings on ERCP showed focal side-branch duct irregularities, main-duct strictures, and grapelike clusters of saccules in seven out of 13 patients (54 %). Seven patients (50 %) underwent pancreatectomy on the basis of abnormal ERCP findings and family history. All 7 patients had widespread ductal epithelial dysplasia (PanIN 1-3); no patient had invasive cancer [76]. The same group subsequently reported another larger series which included 43 individuals from 24 families. In this study EUS was used as first-line imaging modality and ERCP was selectively performed for patients with EUS abnormalities. Twelve patients (28 %) with imaging abnormalities underwent pancreatectomy, two had distal pancreatectomy, and ten had total pancreatectomy. None had evidence of invasive cancer, but all of the cases revealed widespread PanIN lesions involving small and medium-sized ducts [77]. The authors concluded that screening of individuals at high risk using EUS and ERCP is an effective method of identifying precursor lesions before the onset of invasive PC. Of note, such screening is not without its side effects, as pancreatic surgery is associated with significant morbidity, and in ~2 % of the patients even mortality.

The Johns Hopkins group has been conducting a prospective PC screening program on kindred enrolled in NFPTTR, called “Cancer of the Pancreas Screening (CAPS)” [78–80]. The first report from this group consisted of 38 patients from FPC kindreds with mostly more than 2 affected relatives or individuals with Peutz–Jeghers syndrome (PJS). The initial approach was EUS and CT scan, while ERCP was selectively used for EUS abnormalities. As a result, six pancreatic masses were found on EUS: 1 invasive ductal adenocarcinoma, 1 benign IPMN, 2 serous cystadenomas, and 2 non-neoplastic masses, resulting in a diagnostic yield for detecting clinically significant pancreatic neoplasms of 5.3 % (2 of 38) [78]. Subsequently, another prospective trial (CAPS-2) was performed with 78 high-risk individuals (72 from FPC

kindreds and 6 PJS), using annual CT and EUS. If EUS abnormalities were found EUS–fine needle aspiration (FNA) and ERCP was indicated, and surgery was offered when potentially neoplastic lesions were found. Among 78 individuals at high risk who were screened, 17 patients (22 %) had positive imaging, 7 received surgery, and 1 had pathological diagnosis by FNA, resulting in a diagnostic yield of 10 % (8/78) for histologically-proven pancreatic neoplasms; 6 patients had 8 benign IPMNs, 1 had malignant invasive IPMN, and 1 had PanIN. They also noted that many patients with a strong family history of pancreatic cancer have multi-focal PanIN lesions, and that these multifocal PanIN lesions can produce EUS findings similar to those associated with chronic pancreatitis [79, 81].

There have been a number of clinical trials, either single-institution or multicenter, screening individuals at high risk based on FPC registry or hereditary PC-predisposing syndromes, as summarized in Table 4. To date the experience is limited, and there is significant variability among these studies in terms of inclusion criteria, diagnostic modalities, targeted pancreatic lesions for surgical resection, types of surgical resection, etc. The significant questions that remain include:

Who should be screened?

Inclusion criteria for screening have not been consistent. Not surprisingly, diagnostic yield as well as pathological yield has varied among studies as they are highly dependent on the risk level of the individuals screened, sensitivity of the diagnostic imaging, and indication for surgical resection. According to the Fourth International Symposium of Inherited Diseases of the Pancreas [74], a surveillance program is recommended for individuals having more than a 10-fold greater risk for developing PC as compared with the general population. Others have proposed screening for those having a lifetime risk of PC that is ≥ 16 % [82]. A recent international consensus meeting proposed that the following are candidates for screening: first-degree relatives (FDRs) of patients with PC from a familial PC kindred with at least two affected FDRs; patients with Peutz–Jeghers syndrome; and p16, BRCA2, and hereditary nonpolyposis colorectal cancer (HNPCC) mutation carriers with one or more affected FDR [75].

At what age should screening begin?

There is no consensus recommendation on the age to begin screening for individuals at high risk. Screening too early will produce more false positives, while screening too late risks missing a chance to detect and treat curable lesions. Most suggest that screening should be initiated 10 years before the youngest affected family member with PC. In a

report from the Memorial Sloan–Kettering Cancer Center, the yield was highly dependent on the age of the screened relatives, with those ≥ 65 years having a significantly higher yield than those < 65 years [83].

What is the best modality for screening? And how to follow those patients?

Previous studies have employed different modalities, as shown in Table 4. EUS is very sensitive for detecting PC [84], has a negative predictive value of 99–100 %, and has the ability to obtain tissue via FNA [85], which improves the positive predictive value to 99.4 % [85]. On the other hand, EUS is operator-dependent and has a high inter-observer variation [86], and requires sedation. Magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP) has the advantage over CT of avoiding radiation exposure, and it is particularly useful for visualizing cystic lesions such as IPMN [87], as small cysts (branch-duct IPMNs) are the most common abnormality detected in screening [80]. According to the recent guidelines, initial screening should include EUS and MRI/MRCP and ionizing radiation should be limited [75]. These recommendations are based on the prospective CAPS-3 study comparing between CT, MRI/MRCP, and EUS for one-time baseline screening in a blinded fashion [80]. This study found that EUS and MRI/MRCP are better than CT at detecting pancreatic lesions, predominantly cystic lesions [80]. For follow-up, both EUS and MRI/MRCP are modalities preferred by experts, with a 12-month interval [75].

What kind of lesions should be resected? And what type of surgery should be performed?

There is little consensus on making decisions regarding surgical indications for asymptomatic individuals at high risk. This is the most challenging part in a screening program for individuals at high risk to select premalignant lesions for “preventive” surgery, since it is also a potentially unnecessary intervention and clearly can do harm. Given the potential risk of prophylactic pancreatectomy, removing a “still healthy” organ in relatively young asymptomatic patients is not acceptable. Two surgical approaches have been reported (Table 4). The radical approach has been performed by the University of Washington group, conducting total pancreatectomy aiming to remove all precursors involving the pancreas shown by EUS and ERCP, while it has been suggested that a laparoscopic distal pancreatectomy should be performed upfront, and if pathological examination shows abnormal findings then proceed with a complete pancreatectomy [76, 77, 88]. Total pancreatectomy produces brittle diabetes,

Table 4 Summary of screening programs of pancreatic cancer for individuals at high risk

References	Author (year)	Institution	Country	Study period	N	Criteria for high risk	Imaging tests	Diagnostic yield† (%)	Resection (%)	Pathological yield‡ (%)
[76]	Brentnall (1999)	UW	USA	N/A	14	FPC	EUS + ERCP + CT	7‡ (50)	7 (50)	7 (50)
[77]	Kimney (2002)	UW	USA	5 years	46	FPC	EUS ± ERCP	24‡ (52)	12 (26)	12 (26)
[78]	Canto (2004)	JHH	USA	1998–2001	38	FPC, PJS	EUS + CT ± ERCP, EUS-FNA	12 (32)	7 (21)	2 (5.3)
[79]	Canto (2006)	JHH	USA	2001–2004	78	FPC, PJS	EUS + CT ± ERCP, EUS-FNA	17 (22)	7 (9)	8** (10)
[90]	Langer (2009)	FaPaCa	Germany	1999–2007	76	FPC, MPCs	EUS + MRI/MRCP	25 (33)	6 (8)	1 (1.3)
[91]	Poley (2009)	Dutch	Netherlands	2005–2007	44	FPC, FAMMM, PJS, BRCA1/2,	EUS	10 (23)	10 (23)	10 (23)
[92]	Verna (2010)	Columbia U	USA	2005–2008	51	FPC, BRCA1/2, HNPCC, FAMMM	EUS + MRI ± ERCP, EUS-FNA	14 (27)	5 (10)	6** (12)
[83]	Ludwig (2011)	MSKCC	USA	2002–2009	109	FPC, BRCA1/2	MRI/MRCP ± EUS-FNA	9 (8.3)	6 (5.5)	6 (5.5)
[93]	Vasen (2011)	Dutch multi-center	Netherlands	2000–2010	79	FAMMM	MRI/MRCP	16 (20)	5 (6.3)	5 (6.3)
[94]	Zubarik (2011)	UVM/DHMC	USA	2006–2009	27	FPC* w/elevated CA19-9	EUS	7 (26)	3 (11)	2 (7.4)
[46]	Schneider (2011)	FaPaCa	Germany	1999–2009	72	FPC	EUS + MRI/MRCP	10 (14)	9 (13)	6 (8.3)
[95]	Al-Sukhni (2012)	Canada multi-center	Canada	2003–2011	262	FPC, p16, STK11, RCA1/2, PJS, HP	MRI/MRCP ± CT, EUS	19 (7.3)	4 (1.5)	6 (2.3)
[80]	Canto (2012)	US multi-center	USA	N/A	225	FPC, PJS	CT, MRI, EUS	92 (42)	5 (2.2)	5 (2.2)

UW University of Washington, JHH Johns Hopkins Hospital, FaPaCa German national case collection for familial pancreatic cancer, MSKCC, Memorial Sloan–Kettering Cancer Center, UVM University of Vermont, DHMC Dartmouth–Hitchcock Medical Center, FPC familial pancreatic cancer, PJS Peutz–Jeghers syndrome, MPCs melanoma pancreatic cancer syndrome, FAMMM familial atypical multiple mole melanoma, LS Lynch syndrome, LFS Li–Fraumeni syndrome, HNPCC hereditary nonpolyposis colon cancer, HP hereditary pancreatitis, EUS endoscopic ultrasound, ERCP endoscopic retrograde cholangiopancreatography, FNA fine-needle aspiration, CT computed tomography, MRI magnetic resonance imaging, MRCP magnetic resonance cholangiopancreatography

† Only includes pancreatic mass, nodule, and cyst and/or focally dilated pancreatic duct

‡ Includes “chronic pancreatitis-like” lesion

¶ Defined as pathologically proven (pre)malignant lesion (pancreatic adenocarcinoma, IPMN, MCN, PanIN-2/3, and neuroendocrine tumor)

* In this series FPC was defined as at least 1 FDR with PC

*** Also included biopsy results

and death has been reported in a patient who underwent total pancreatectomy [76, 89]. On the other hand, because of the real risks associated with total pancreatectomy, the Johns Hopkins group and following series support partial pancreatectomy, targeting the removal of solid (nodular) or cystic lesions detected by EUS or MRI/MRCP [46, 78–80, 83, 90–95]. Whichever approach is chosen, pancreatectomy should be performed at a center experienced in pancreatic disease involving a multi-disciplinary team including gastroenterology, surgery, radiology, and pathology.

The majority of lesions detected by screening programs to date include small branch-duct IPMNs and PanINs [46, 76–80, 83, 90–95]. In the international consensus guidelines for cystic neoplasms (Sendai guidelines), it is widely accepted that surgical resection for branch-duct IPMN is recommended if the tumor size is over 3 cm or if a mural nodule (solid component) is observed [69, 73]. There remains no consensus on whether smaller branch-duct IPMNs in individuals at high risk should be resected or not.

Finally, like other malignancies [96, 97], screening of PC for individuals at high risk will not be justified unless survival benefit and cost-effectiveness is proven; this requires a large-scale multicenter study with long-term follow-up.

Basic research based on the Familial Pancreatic Cancer Registry

A number of familial pancreatic cancer genes have been identified. These genes account for some, but not all of the familial aggregation of pancreatic cancer. Germline *BRCA2* mutations cause up to 17–19 % of FPC, making *BRCA2* the most common genetic abnormality among FPC kindreds [32, 98]. Germline *BRCA2* gene mutations are particularly common in the Ashkenazi Jewish population. Recently the *PALB2* gene, partner and localizer of breast cancer 2 gene, was identified as a FPC susceptibility gene by sequencing of all protein-coding genes in a single FPC patient and their cancer [99]. Subsequent studies suggest that *PALB2* accounts for about 3 % of FPC [100]. Whole-exome sequencing of relatives with pancreatic cancer enrolled in the NFPTR led to the discovery of *ATM* as a FPC gene [101].

As next-generation sequencing technology improves in speed and cost, it will certainly add to our understanding of the genes responsible for the familial clustering of PC. The best way to ensure that individuals of Japanese heritage are included in these exciting studies, and that genes responsible for the aggregation of PC in Japanese patients are discovered, is to establish FPC registries in Japan.

Familial Pancreatic Cancer Registry in Japan and future direction

Formal FPC registries have not yet been established in Japan, but case reports and case-control studies suggest that the incidence of FPC in Japan is similar to that in the USA and European countries [102–104]. Recently, Matsubayashi and colleague [104] conducted a case-control study comparing 577 patients with PC and the same number of age-matched controls, showing that the incidence of having a first-degree relative with PC is significantly higher in patients with PC (6.9 %) than controls (2.9 %), with an odds ratio of 2.5 ($P = 0.02$).

There is obviously a need for a FPC registry in Japan in order to align pancreatic cancer research in Japan with international efforts to study familial pancreatic cancer. Establishing such registries in Japan is critical, as it will lead to a better understanding of the natural history, risk factors, and responsible genes in the Japanese population. These advances, in turn, will improve survival by allowing effective screening programs to be applied to individuals at high risk. Although there are very many questions that must be answered in this subject, the initial step is full awareness of the clinical importance of family history in patients with PC by individual physicians and medical staff, as well as the patients themselves and their families.

References

1. <http://ganjoho.jp/professional/statistics/statistics.html>. Center for Cancer Control and Information Services, National Cancer Center, Japan. Accessed 04 Mar 2013
2. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, et al. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. *Pancreas*. 2012;41:985–92.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin*. 2010;60:277–300.
4. Ikeda M, Sato T, Morozumi A, Fujino MA, Yoda Y, Ochiai M, et al. Morphologic changes in the pancreas detected by screening ultrasonography in a mass survey, with special reference to main duct dilatation, cyst formation, and calcification. *Pancreas*. 1994;9:508–12.
5. Kuroki-Suzuki S, Kuroki Y, Nasu K, Nagashima C, Machida M, Muramatsu Y, et al. Pancreatic cancer screening employing noncontrast magnetic resonance imaging combined with ultrasonography. *Jpn J Radiol*. 2011;29:265–71.
6. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. *Langenbecks Arch Surg*. 2008;393:535–45.
7. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. *Am J Epidemiol*. 2009;170:403–13.
8. Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. Cigarette smoking and pancreatic cancer: an

- analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). *Ann Oncol.* 2012;23:1880–8.
9. Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. *J Surg Oncol.* 2013;107:1–7.
 10. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med.* 2003;348:1625–38.
 11. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. *Int J Cancer.* 2007;120:1993–8.
 12. Genkinger JM, Spiegelman D, Anderson KE, Bergkvist L, Bernstein L, van den Brandt PA, et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. *Cancer Epidemiol Biomarkers Prev.* 2009;18:765–76.
 13. Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). *Ann Oncol.* 2012;23:374–82.
 14. Huxley R, Ansary-Moghaddam A, de Gonzalez BA, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. *Br J Cancer.* 2005;92:2076–83.
 15. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. *Lancet Oncol.* 2009;10:88–95.
 16. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. *Eur J Cancer.* 2011;47:1928–37.
 17. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. *N Engl J Med.* 1993;328:1433–7.
 18. Talamini G, Falconi M, Bassi C, Sartori N, Salvia R, Caldiron E, et al. Incidence of cancer in the course of chronic pancreatitis. *Am J Gastroenterol.* 1999;94:1253–60.
 19. Tanno S, Nakano Y, Koizumi K, Sugiyama Y, Nakamura K, Sasajima J, et al. Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. *Pancreas.* 2010;39:36–40.
 20. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology.* 2000;119:1447–53.
 21. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. *Am J Gastroenterol.* 2010;105:1258–64. author reply 1265.
 22. Lowenfels AB, Maisonneuve P, DiMaggio EP, Elitsur Y, Gates LK Jr, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. *J Natl Cancer Inst.* 1997;89:442–6.
 23. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. *Clin Gastroenterol Hepatol.* 2004;2:252–61.
 24. Rebours V, Boutron-Ruault MC, Schneé M, Ferec C, Maire F, Hammel P, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. *Am J Gastroenterol.* 2008;103:111–9.
 25. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. *J Natl Cancer Inst.* 2000;92:1260–6.
 26. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). *Int J Cancer.* 2000;87:809–11.
 27. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. *J Med Genet.* 2007;44:99–106.
 28. Lynch HT, Fusaro RM, Lynch JF, Brand R. Pancreatic cancer and the FAMMM syndrome. *Fam Cancer.* 2008;7:103–12.
 29. Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. *Cancer Res.* 2000;60:409–16.
 30. Naderi A, Couch FJ. BRCA2 and pancreatic cancer. *Int J Gastrointest Cancer.* 2002;31:99–106.
 31. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. *J Natl Cancer Inst.* 2002;94:1358–65.
 32. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, et al. BRCA2 germline mutations in familial pancreatic carcinoma. *J Natl Cancer Inst.* 2003;95:214–21.
 33. Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. *Cancer Epidemiol Biomarkers Prev.* 2007;16:342–6.
 34. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. *Br J Cancer.* 1985;52:271–3.
 35. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer.* 1999;81:214–8.
 36. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer.* 2008;123:444–9.
 37. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA.* 2009;302:1790–5.
 38. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. *Adv Surg.* 2010;44:293–311.
 39. Matsubayashi H. Familial pancreatic cancer and hereditary syndromes: screening strategy for high-risk individuals. *J Gastroenterol.* 2011;46:1249–59.
 40. Hruban RH, Petersen GM, Ha PK, Kern SE. Genetics of pancreatic cancer. From genes to families. *Surg Oncol Clin N Am.* 1998;7:1–23.
 41. Banke MG, Mulvihill JJ, Aston CE. Inheritance of pancreatic cancer in pancreatic cancer-prone families. *Med Clin North Am.* 2000;84:677–90. x–xi.
 42. Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. *Curr Treat Options Oncol.* 2005;6:437–45.
 43. Petersen GM, de Andrade M, Goggins M, Hruban RH, Bondy M, Korczak JF, et al. Pancreatic cancer genetic epidemiology consortium. *Cancer Epidemiol Biomarkers Prev.* 2006;15:704–10.
 44. Raimondi S, Maisonneuve P, Lohr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. *Cancer Epidemiol Biomarkers Prev.* 2007;16:1894–7.
 45. McFaul CD, Greenhalf W, Earl J, Howes N, Neoptolemos JP, Kress R, et al. Anticipation in familial pancreatic cancer. *Gut.* 2006;55:252–8.
 46. Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthai E, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. *Fam Cancer.* 2011;10:323–30.
 47. Wang L, Brune KA, Visvanathan K, Laheru D, Herman J, Wolfgang C, et al. Elevated cancer mortality in the relatives of

- patients with pancreatic cancer. *Cancer Epidemiol Biomarkers Prev.* 2009;18:2829–34.
48. Lynch HT, Anderson DE, Krush AJ. Heredity, cancer, and the genetics clinic. *Tex Med.* 1967;63:57–61.
 49. MacDermott RP, Kramer P. Adenocarcinoma of the pancreas in four siblings. *Gastroenterology.* 1973;65:137–9.
 50. Friedman JM, Fialkow PJ. Carcinoma of the pancreas in four brothers. *Birth Defects Orig Artic Ser.* 1976;12:145–50.
 51. Reimer RR, Fraumeni JF, Jr, Ozols RF, Bender R. Pancreatic cancer in father and son. *Lancet.* 1977;1:911.
 52. Dat NM, Sontag SJ. Pancreatic carcinoma in brothers. *Ann Intern Med.* 1982;97:282.
 53. Katkhouda N, Mouiel J. Pancreatic cancer in mother and daughter. *Lancet.* 1986;2:747.
 54. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. *Int J Pancreatol.* 1991;10:183–96.
 55. Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, et al. Risk factors for pancreatic cancer: case-control study. *Am J Gastroenterol.* 2007;102:2696–707.
 56. Anderson LN, Cotterchio M, Gallinger S. Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada. *Cancer Causes Control.* 2009;20:825–34.
 57. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. *PLoS Med.* 2004;1:e65.
 58. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. *Cancer Causes Control.* 2000;11:915–23.
 59. Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. *Int J Cancer.* 2003;103:525–30.
 60. Jacobs EJ, Rodriguez C, Newton CC, Bain EB, Patel AV, Feigelson HS, et al. Family history of various cancers and pancreatic cancer mortality in a large cohort. *Cancer Causes Control.* 2009;20:1261–9.
 61. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res.* 2004;64:2634–8.
 62. Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. *J Clin Oncol.* 2007;25:1417–22.
 63. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. *Clin Cancer Res.* 2000;6:2969–72.
 64. Luttges J, Kloppel G. Precancerous conditions of pancreatic carcinoma. *J Hepatobiliary Pancreat Surg.* 2000;7:568–74.
 65. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *Am J Surg Pathol.* 2004;28:977–87.
 66. Takaori K, Hruban RH, Maitra A, Tanigawa N. Pancreatic intraepithelial neoplasia. *Pancreas.* 2004;28:257–62.
 67. Hruban RH, Takaori K, Canto M, Fishman EK, Campbell K, Brune K, et al. Clinical importance of precursor lesions in the pancreas. *J Hepatobiliary Pancreat Surg.* 2007;14:255–63.
 68. Sakorafas GH, Sarr MG. Cystic neoplasms of the pancreas; what a clinician should know. *Cancer Treat Rev.* 2005;31:507–35.
 69. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. *Pancreatology.* 2006;6:17–32.
 70. Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, Sarr MG. Primary pancreatic cystic neoplasms revisited. Part III. Intraductal papillary mucinous neoplasms. *Surg Oncol.* 2011;20:e109–18.
 71. Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, Sarr MG. Primary pancreatic cystic neoplasms revisited: part II. Mucinous cystic neoplasms. *Surg Oncol.* 2011;20:e93–101.
 72. Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, Sarr MG. Primary pancreatic cystic neoplasms revisited. Part I: serous cystic neoplasms. *Surg Oncol.* 2011;20:e84–92.
 73. Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. *Pancreatology.* 2012;12:183–97.
 74. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. *Gut.* 2007;56:1460–9.
 75. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut.* 2013;62:339–47.
 76. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. *Ann Intern Med.* 1999;131:247–55.
 77. Kimmey MB, Bronner MP, Byrd DR, Brentnall TA. Screening and surveillance for hereditary pancreatic cancer. *Gastrointest Endosc.* 2002;56:S82–6.
 78. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. *Clin Gastroenterol Hepatol.* 2004;2:606–21.
 79. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. *Clin Gastroenterol Hepatol.* 2006;4:766–81. quiz 665.
 80. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. *Gastroenterology.* 2012;142:796–804. quiz e714–795.
 81. Brune K, Abe T, Canto M, O'Malley L, Klein AP, Maitra A, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. *Am J Surg Pathol.* 2006;30:1067–76.
 82. Brentnall TA. Pancreatic cancer surveillance: learning as we go. *Am J Gastroenterol.* 2011;106:955–6.
 83. Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. *Am J Gastroenterol.* 2011;106:946–54.
 84. DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. *Ann Intern Med.* 2004;141:753–63.
 85. Volmar KE, Vollmer RT, Jowell PS, Nelson RC, Xie HB. Pancreatic FNA in 1000 cases: a comparison of imaging modalities. *Gastrointest Endosc.* 2005;61:854–61.
 86. Ahmad NA, Kochman ML, Brensinger C, Brugge WR, Faigel DO, Gress FG, et al. Interobserver agreement among endosonographers for the diagnosis of neoplastic versus non-neoplastic pancreatic cystic lesions. *Gastrointest Endosc.* 2003;58:59–64.
 87. Ku YM, Shin SS, Lee CH, Semelka RC. Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms. *Top Magn Reson Imaging.* 2009;20:11–8.

88. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. *Pancreatology*. 2001;1:477–85.
89. Evans JP, Burke W, Chen R, Bennett RL, Schmidt RA, Dellinger EP, et al. Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. *J Med Genet*. 1995;32:330–5.
90. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. *Gut*. 2009;58:1410–8.
91. Poley JW, Kluijdt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. *Am J Gastroenterol*. 2009;104:2175–81.
92. Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. *Clin Cancer Res*. 2010;16:5028–37.
93. Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis NA, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. *Gastroenterology*. 2011;140:850–6.
94. Zubarik R, Gordon SR, Lidofsky SD, Anderson SR, Pipas JM, Badger G, et al. Screening for pancreatic cancer in a high-risk population with serum CA 19–9 and targeted EUS: a feasibility study. *Gastrointest Endosc*. 2011;74:87–95.
95. Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. *J Gastrointest Surg*. 2012;16:771–83.
96. Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. *J Clin Epidemiol*. 2011;64:1412–7.
97. Puliti D, Zappa M. Breast cancer screening: are we seeing the benefit? *BMC Med*. 2012;10:106.
98. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. *Cancer Res*. 2002;62:3789–93.
99. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science*. 2009;324:217.
100. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, et al. PALB2 mutations in European familial pancreatic cancer families. *Clin Genet*. 2010;78:490–4.
101. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov*. 2012;2:41–6.
102. Yamaguchi K, Kinoshita H, Hokazono K, Kawamoto M, Yamamoto H, Sugitani A, et al. Familial pancreatic cancer: report of one Japanese family. *J Hepatobiliary Pancreat Surg*. 2004;11:434–7.
103. Inoue M, Tajima K, Takezaki T, Hamajima N, Hirose K, Ito H, et al. Epidemiology of pancreatic cancer in Japan: a nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). *Int J Epidemiol*. 2003;32:257–62.
104. Matsubayashi H, Maeda A, Kanemoto H, Uesaka K, Yamazaki K, Hironaka S, et al. Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes. *Pancreas*. 2011;40:974–8.